BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Winter JM, Brennan MF, Tang LH, D’angelica MI, Dematteo RP, Fong Y, Klimstra DS, Jarnagin WR, Allen PJ. Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades. Ann Surg Oncol 2012;19:169-75. [DOI: 10.1245/s10434-011-1900-3] [Cited by in Crossref: 244] [Cited by in F6Publishing: 217] [Article Influence: 24.4] [Reference Citation Analysis]
Number Citing Articles
1 Bradley A, Van der Meer R, McKay CJ. A prognostic Bayesian network that makes personalized predictions of poor prognostic outcome post resection of pancreatic ductal adenocarcinoma. PLoS One 2019;14:e0222270. [PMID: 31498836 DOI: 10.1371/journal.pone.0222270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lowder CY, Metkus J, Epstein J, Kozak GM, Lavu H, Yeo CJ, Winter JM. Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer. Ann Surg Oncol 2018;25:4004-11. [PMID: 30225835 DOI: 10.1245/s10434-018-6763-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
3 Sallinen VJ, Le Large TYS, Tieftrunk E, Galeev S, Kovalenko Z, Haugvik SP, Antila A, Franklin O, Martinez-Moneo E, Robinson SM, Panzuto F, Regenet N, Muffatti F, Partelli S, Wiese D, Ruszniewski P, Dousset B, Edwin B, Bartsch DK, Sauvanet A, Falconi M, Ceyhan GO, Gaujoux S; Pancreas 2000 research group. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. HPB (Oxford) 2018;20:251-9. [PMID: 28988702 DOI: 10.1016/j.hpb.2017.08.034] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
4 Tzeng CW, Katz MH, Fleming JB, Lee JE, Pisters PW, Holmes HM, Varadhachary GR, Wolff RA, Abbruzzese JL, Vauthey JN. Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg. 2014;18:146-55; discussion 155-6. [PMID: 24129825 DOI: 10.1007/s11605-013-2371-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
5 [DOI: 10.1101/454397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Fong ZV, Tan WP, Lavu H, Kennedy EP, Mitchell DG, Koniaris LG, Sauter PK, Rosato EL, Yeo CJ, Winter JM. Preoperative imaging for resectable periampullary cancer: clinicopathologic implications of reported radiographic findings. J Gastrointest Surg 2013;17:1098-106. [PMID: 23553385 DOI: 10.1007/s11605-013-2181-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
7 Fong ZV, Hashimoto DA, Jin G, Haynes AB, Perez N, Qadan M, Ferrone CR, Fernandez-Del Castillo C, Warshaw AL, Lillemoe KD, Traeger LN, Chang DC. Simulated Volume-Based Regionalization of Complex Procedures: Impact on Spatial Access to Care. Ann Surg 2021;274:312-8. [PMID: 31449139 DOI: 10.1097/SLA.0000000000003574] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Aslakson RA, Chandrashekaran SV, Rickerson E, Fahy BN, Johnston FM, Miller JA, Conca-Cheng A, Wang S, Morris AM, Lorenz K, Temel JS, Smith TJ. A Multicenter, Randomized Controlled Trial of Perioperative Palliative Care Surrounding Cancer Surgery for Patients and Their Family Members (PERIOP-PC). J Palliat Med 2019;22:44-57. [PMID: 31486730 DOI: 10.1089/jpm.2019.0130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
9 Storck H, Hild B, Schimmelpfennig S, Sargin S, Nielsen N, Zaccagnino A, Budde T, Novak I, Kalthoff H, Schwab A. Ion channels in control of pancreatic stellate cell migration. Oncotarget 2017;8:769-84. [PMID: 27903970 DOI: 10.18632/oncotarget.13647] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
10 Mezhir JJ, McDowell BD. Pancreaticobiliary surgery for the treatment of malignancy: spread the word. J Surg Res 2013;185:513-5. [PMID: 23043864 DOI: 10.1016/j.jss.2012.09.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Younan G. Pancreas Solid Tumors. Surg Clin North Am 2020;100:565-80. [PMID: 32402301 DOI: 10.1016/j.suc.2020.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, Smaaland R, Sorbye H, Verbeke C, Dueland S. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial. BMC Surg 2017;17:94. [PMID: 28841916 DOI: 10.1186/s12893-017-0291-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 10.8] [Reference Citation Analysis]
13 Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15-22. [PMID: 22729569 DOI: 10.1002/jso.23192] [Cited by in Crossref: 137] [Cited by in F6Publishing: 131] [Article Influence: 15.2] [Reference Citation Analysis]
14 de Geus SW, Evans DB, Bliss LA, Eskander MF, Smith JK, Wolff RA, Miksad RA, Weinstein MC, Tseng JF. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. Eur J Surg Oncol. 2016;42:1552-1560. [PMID: 27570116 DOI: 10.1016/j.ejso.2016.07.016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
15 van Mackelenbergh MG, Stroes CI, Spijker R, van Eijck CHJ, Wilmink JW, Bijlsma MF, van Laarhoven HWM. Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 31035512 DOI: 10.3390/cancers11050588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
16 Wang SC, Parekh JR, Porembka MR, Nathan H, D'Angelica MI, DeMatteo RP, Fong Y, Kingham TP, Jarnagin WR, Allen PJ. A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. J Gastrointest Surg 2016;20:899-904. [PMID: 26921028 DOI: 10.1007/s11605-015-3057-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
17 Choi MH, Yoon SB, Lee K, Song M, Lee IS, Lee MA, Hong TH, Choi MG. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. J Cachexia Sarcopenia Muscle. 2018;9:326-334. [PMID: 29399990 DOI: 10.1002/jcsm.12274] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 16.0] [Reference Citation Analysis]
18 Asare EA, Evans DB, Erickson BA, Aburajab M, Tolat P, Tsai S. Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. J Surg Oncol 2016;114:291-5. [PMID: 27264017 DOI: 10.1002/jso.24316] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
19 Amini N, Spolverato G, Kim Y, Pawlik TM. Trends in Hospital Volume and Failure to Rescue for Pancreatic Surgery. J Gastrointest Surg. 2015;19:1581-1592. [PMID: 25794484 DOI: 10.1007/s11605-015-2800-9] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 14.3] [Reference Citation Analysis]
20 Barnes CA, Krepline AN, Aldakkak M, Clarke CN, Christians KK, Khan AH, Hunt BC, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? J Gastrointest Surg. 2017;21:1793-1803. [PMID: 28849366 DOI: 10.1007/s11605-017-3544-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
21 Yabar CS, Winter JM. Pancreatic Cancer: A Review. Gastroenterol Clin North Am. 2016;45:429-445. [PMID: 27546841 DOI: 10.1016/j.gtc.2016.04.003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 12.8] [Reference Citation Analysis]
22 Su MJ, Aldawsari H, Amiji M. Pancreatic Cancer Cell Exosome-Mediated Macrophage Reprogramming and the Role of MicroRNAs 155 and 125b2 Transfection using Nanoparticle Delivery Systems. Sci Rep. 2016;6:30110. [PMID: 27443190 DOI: 10.1038/srep30110] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 16.0] [Reference Citation Analysis]
23 Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, Evans DB, Tsai S. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 2016;159:893-900. [PMID: 26602840 DOI: 10.1016/j.surg.2015.09.018] [Cited by in Crossref: 86] [Cited by in F6Publishing: 66] [Article Influence: 17.2] [Reference Citation Analysis]
24 Andersen LMK, Wegner CS, Simonsen TG, Huang R, Gaustad JV, Hauge A, Galappathi K, Rofstad EK. Lymph node metastasis and the physicochemical micro-environment of pancreatic ductal adenocarcinoma xenografts. Oncotarget 2017;8:48060-74. [PMID: 28624797 DOI: 10.18632/oncotarget.18231] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
25 Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012;18:530-538. [PMID: 23187839 DOI: 10.1097/ppo.0b013e31827654ea] [Cited by in Crossref: 71] [Cited by in F6Publishing: 40] [Article Influence: 8.9] [Reference Citation Analysis]
26 Waldeland JO, Gaustad JV, Rofstad EK, Evje S. In silico investigations of intratumoral heterogeneous interstitial fluid pressure. J Theor Biol 2021;526:110787. [PMID: 34087266 DOI: 10.1016/j.jtbi.2021.110787] [Reference Citation Analysis]
27 Alemi F, Alseidi A, Scott Helton W, Rocha FG. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. Curr Probl Surg 2015;52:362-98. [PMID: 26363649 DOI: 10.1067/j.cpsurg.2015.07.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:1168-1175. [PMID: 25352267 DOI: 10.1245/s10434-014-4192-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 9.7] [Reference Citation Analysis]
29 Datta J, Wilson GC, D'Angelica MI, Katz MHG, Maithel SK, Merchant NB, Ahmad SA. A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer: Let the Data Speak. Ann Surg 2021;274:e82-4. [PMID: 33086320 DOI: 10.1097/SLA.0000000000004471] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Ryska M, Rudis J. Pancreatic fistula and postoperative pancreatitis after pancreatoduodenectomy for pancreatic cancer. Hepatobiliary Surg Nutr 2014;3:268-75. [PMID: 25392838 DOI: 10.3978/j.issn.2304-3881.2014.09.05] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
31 Gavazzi F, Capretti G, Giordano L, Ridolfi C, Spaggiari P, Sollai M, Carrara S, Nappo G, Bozzarelli S, Zerbi A. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival. Dig Liver Dis 2021:S1590-8658(21)00322-4. [PMID: 34219044 DOI: 10.1016/j.dld.2021.06.006] [Reference Citation Analysis]
32 Witkowski ER, Smith JK, Tseng JF. Outcomes following resection of pancreatic cancer. J Surg Oncol. 2013;107:97-103. [PMID: 22991309 DOI: 10.1002/jso.23267] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
33 Radomski M, Zenati M, Novak S, Tam V, Steve J, Bartlett DL, Zureikat AH, Zeh HJ 3rd, Hogg ME. Factors associated with prolonged hospitalization in patients undergoing pancreatoduodenectomy. Am J Surg 2018;215:636-42. [PMID: 28958654 DOI: 10.1016/j.amjsurg.2017.06.040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
34 Epstein JD, Kozak G, Fong ZV, He J, Javed AA, Joneja U, Jiang W, Ferrone CR, Lillemoe KD, Cameron JL, Weiss MJ, Lavu H, Yeo CJ, Fernandez-Del Castillo C, Wolfgang CL, Winter JM. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. J Surg Oncol 2017;116:658-64. [PMID: 28628722 DOI: 10.1002/jso.24723] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
35 Joglekar S, Asghar A, Mott SL, Johnson BE, Button AM, Clark E, Mezhir JJ. Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J Surg Oncol. 2015;111:771-775. [PMID: 25556324 DOI: 10.1002/jso.23862] [Cited by in Crossref: 155] [Cited by in F6Publishing: 127] [Article Influence: 22.1] [Reference Citation Analysis]
36 Haugvik SP, Janson ET, Österlund P, Langer SW, Falk RS, Labori KJ, Vestermark LW, Grønbæk H, Gladhaug IP, Sorbye H. Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. Ann Surg Oncol 2016;23:1721-8. [PMID: 26678407 DOI: 10.1245/s10434-015-5013-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
37 Peng J, Sun BF, Chen CY, Zhou JY, Chen YS, Chen H, Liu L, Huang D, Jiang J, Cui GS, Yang Y, Wang W, Guo D, Dai M, Guo J, Zhang T, Liao Q, Liu Y, Zhao YL, Han DL, Zhao Y, Yang YG, Wu W. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res 2019;29:725-38. [PMID: 31273297 DOI: 10.1038/s41422-019-0195-y] [Cited by in Crossref: 164] [Cited by in F6Publishing: 126] [Article Influence: 82.0] [Reference Citation Analysis]
38 Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford) 2015;17:942-52. [PMID: 26255895 DOI: 10.1111/hpb.12448] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
39 Amini N, Spolverato G, Gupta R, Margonis GA, Kim Y, Wagner D, Rezaee N, Weiss MJ, Wolfgang CL, Makary MM, Kamel IR, Pawlik TM. Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia. J Gastrointest Surg. 2015;19:1593-1602. [PMID: 25925237 DOI: 10.1007/s11605-015-2835-y] [Cited by in Crossref: 113] [Cited by in F6Publishing: 104] [Article Influence: 18.8] [Reference Citation Analysis]
40 Shi X, Peng J, Jiang H, Gao Y, Wang W, Zhou F. Impact of Adjuvant Chemoradiotherapy on Survival of Resected Pancreatic Adenocarcinoma Cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis. Front Oncol 2021;11:651671. [PMID: 34277405 DOI: 10.3389/fonc.2021.651671] [Reference Citation Analysis]
41 Li S, Tian B. Acute pancreatitis in patients with pancreatic cancer: Timing of surgery and survival duration. Medicine (Baltimore). 2017;96:e5908. [PMID: 28099352 DOI: 10.1097/md.0000000000005908] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
42 Takahashi C, Shridhar R, Huston J, Meredith K. Correlation of tumor size and survival in pancreatic cancer. J Gastrointest Oncol 2018;9:910-21. [PMID: 30505594 DOI: 10.21037/jgo.2018.08.06] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
43 Nakagawa N, Yamada S, Sonohara F, Takami H, Hayashi M, Kanda M, Kobayashi D, Tanaka C, Nakayama G, Koike M, Fujiwara M, Kodera Y. Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer. Ann Surg Oncol 2020;27:887-95. [PMID: 31848811 DOI: 10.1245/s10434-019-08047-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
44 Tsai S, Christians KK, Ritch PS, George B, Khan AH, Erickson B, Evans DB. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. J Oncol Pract 2016;12:915-23. [PMID: 27858562 DOI: 10.1200/JOP.2016.016162] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
45 Razzaque MS, Atfi A. TGIF1-Twist1 axis in pancreatic ductal adenocarcinoma. Comput Struct Biotechnol J 2020;18:2568-72. [PMID: 33005315 DOI: 10.1016/j.csbj.2020.09.023] [Reference Citation Analysis]
46 Erkan M. Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis. J Pathol. 2013;231:4-7. [PMID: 23716361 DOI: 10.1002/path.4213] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
47 Fong ZV, Ferrone CR, Lillemoe KD, Fernández-Del Castillo C. Intraductal Papillary Mucinous Neoplasm of the Pancreas: Current State of the Art and Ongoing Controversies. Ann Surg 2016;263:908-17. [PMID: 26727096 DOI: 10.1097/SLA.0000000000001567] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 3.4] [Reference Citation Analysis]
48 Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 2012;9:454-67. [PMID: 22710569 DOI: 10.1038/nrgastro.2012.115] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
49 Nikfarjam M, Yeo D, He H, Baldwin G, Fifis T, Costa P, Tan B, Yang E, Wen Sw, Christophi C. Comparison of two syngeneic orthotopic murine models of pancreatic adenocarcinoma. J Invest Surg 2013;26:352-9. [PMID: 23957638 DOI: 10.3109/08941939.2013.797057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
50 Tang Y, Zheng Y, Chen X, Wang W, Guo Q, Shu J, Wu J, Su S. Identifying Periampullary Regions in MRI Images Using Deep Learning. Front Oncol 2021;11:674579. [PMID: 34123843 DOI: 10.3389/fonc.2021.674579] [Reference Citation Analysis]
51 Marmor S, Burke EE, Virnig BA, Jensen EH, Tuttle TM. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas: Surgical Treatment for Pancreatic Cancer. Cancer 2016;122:3378-85. [DOI: 10.1002/cncr.30199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
52 Tran TB, Maker VK, Maker AV. Impact of Immunotherapy after Resection of Pancreatic Cancer. J Am Coll Surg 2019;229:19-27.e1. [PMID: 30742911 DOI: 10.1016/j.jamcollsurg.2019.01.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
53 Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MH. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2541-2556. [PMID: 27247221 DOI: 10.1200/jco.2016.67.5553] [Cited by in Crossref: 195] [Cited by in F6Publishing: 69] [Article Influence: 39.0] [Reference Citation Analysis]
54 Untch BR, Allen PJ. Pancreatic metastasectomy: the Memorial Sloan-Kettering experience and a review of the literature. J Surg Oncol. 2014;109:28-30. [PMID: 24122337 DOI: 10.1002/jso.23460] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
55 El Nakeeb A, El Sorogy M, Ezzat H, Said R, El Dosoky M, Abd El Gawad M, Elsabagh AM, El Hanafy E. Predictors of long-term survival after pancreaticoduodenectomy for peri-ampullary adenocarcinoma: A retrospective study of 5-year survivors. Hepatobiliary Pancreat Dis Int 2018;17:443-9. [PMID: 30126828 DOI: 10.1016/j.hbpd.2018.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
56 Picozzi VJ, Oh SY, Edwards A, Mandelson MT, Dorer R, Rocha FG, Alseidi A, Biehl T, Traverso LW, Helton WS, Kozarek RA. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Ann Surg Oncol 2017;24:1722-30. [PMID: 28054192 DOI: 10.1245/s10434-016-5716-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
57 Hao S, Takahashi C, Snyder RA, Parikh AA. Stratifying Intraductal Papillary Mucinous Neoplasms by Cyst Fluid Analysis: Present and Future. Int J Mol Sci. 2020;21. [PMID: 32050465 DOI: 10.3390/ijms21031147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Marzec J, Dayem Ullah AZ, Pirrò S, Gadaleta E, Crnogorac-Jurcevic T, Lemoine NR, Kocher HM, Chelala C. The Pancreatic Expression Database: 2018 update. Nucleic Acids Res 2018;46:D1107-10. [PMID: 29059374 DOI: 10.1093/nar/gkx955] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
59 Li Y, Zhao Z, Liu H, Fetse JP, Jain A, Lin CY, Cheng K. Development of a Tumor-Responsive Nanopolyplex Targeting Pancreatic Cancer Cells and Stroma. ACS Appl Mater Interfaces 2019;11:45390-403. [PMID: 31769963 DOI: 10.1021/acsami.9b15116] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
60 Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, Sho M, Tsuchida A, Unno M; Study Group of Preoperative therapy for Pancreatic cancer (PREP). A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol 2019;54:194-203. [PMID: 30182219 DOI: 10.1007/s00535-018-1506-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
61 Iacobuzio-Donahue CA, Michael C, Baez P, Kappagantula R, Hooper JE, Hollman TJ. Cancer biology as revealed by the research autopsy. Nat Rev Cancer 2019;19:686-97. [PMID: 31519982 DOI: 10.1038/s41568-019-0199-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
62 Shaib WL, Zakka K, Shahin AA, Yared F, Switchenko JM, Wu C, Akce M, Alese OB, Patel PR, Mcdonald M, El-Rayes BF. Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Pancreas 2020;49:822-9. [PMID: 32541638 DOI: 10.1097/MPA.0000000000001584] [Reference Citation Analysis]
63 Bradley A, van der Meer R, McKay C. Personalized Pancreatic Cancer Management: A Systematic Review of How Machine Learning Is Supporting Decision-making. Pancreas 2019;48:598-604. [PMID: 31090660 DOI: 10.1097/MPA.0000000000001312] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
64 Turrini O, Ewald J, Barbier L, Mokart D, Blache JL, Delpero JR. Should the portal vein be routinely resected during pancreaticoduodenectomy for adenocarcinoma? Ann Surg. 2013;257:726-730. [PMID: 22968078 DOI: 10.1097/sla.0b013e318269d23c] [Cited by in Crossref: 60] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
65 Nordby T, Hugenschmidt H, Fagerland MW, Ikdahl T, Buanes T, Labori KJ. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival. Eur J Surg Oncol. 2013;39:559-566. [PMID: 23498362 DOI: 10.1016/j.ejso.2013.02.020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
66 Bliss LA, Witkowski ER, Yang CJ, Tseng JF. Outcomes in operative management of pancreatic cancer. J Surg Oncol 2014;110:592-8. [PMID: 25111970 DOI: 10.1002/jso.23744] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
67 Miura JT, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Oshima K, Christians KK, Evans DB, Tsai S. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery 2015;158:1545-55. [PMID: 26243342 DOI: 10.1016/j.surg.2015.06.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
68 Nichols RC, Rutenberg M. Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protons. World J Gastrointest Surg. 2019;11:303-307. [PMID: 31602289 DOI: 10.4240/wjgs.v11.i7.303] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
69 Burke EE, Marmor S, Portschy PR, Virnig BA, Cho LC, Tuttle TM, Jensen EH. Trends in the use of pre-operative radiation for adenocarcinoma of the pancreas in the United States. HPB (Oxford) 2015;17:542-50. [PMID: 25726950 DOI: 10.1111/hpb.12400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Mezhir JJ. Management of complications following pancreatic resection: An evidence-based approach: Pancreatectomy Complications. J Surg Oncol 2013;107:58-66. [DOI: 10.1002/jso.23139] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
71 Shakir M, Boone BA, Polanco PM, Zenati MS, Hogg ME, Tsung A, Choudry HA, Moser AJ, Bartlett DL, Zeh HJ. The learning curve for robotic distal pancreatectomy: an analysis of outcomes of the first 100 consecutive cases at a high-volume pancreatic centre. HPB (Oxford). 2015;17:580-586. [PMID: 25906690 DOI: 10.1111/hpb.12412] [Cited by in Crossref: 102] [Cited by in F6Publishing: 72] [Article Influence: 17.0] [Reference Citation Analysis]
72 Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019;18:14. [PMID: 30665410 DOI: 10.1186/s12943-018-0927-5] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 46.5] [Reference Citation Analysis]
73 Correa-Gallego C, Dinkelspiel HE, Sulimanoff I, Fisher S, Viñuela EF, Kingham TP, Fong Y, DeMatteo RP, D'Angelica MI, Jarnagin WR, Allen PJ. Minimally-invasive vs open pancreaticoduodenectomy: systematic review and meta-analysis. J Am Coll Surg 2014;218:129-39. [PMID: 24275074 DOI: 10.1016/j.jamcollsurg.2013.09.005] [Cited by in Crossref: 112] [Cited by in F6Publishing: 90] [Article Influence: 14.0] [Reference Citation Analysis]
74 Pugalenthi A, Protic M, Gonen M, Kingham TP, Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ. Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. J Surg Oncol. 2016;113:188-193. [PMID: 26678349 DOI: 10.1002/jso.24125] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 11.3] [Reference Citation Analysis]
75 Perone JA, Riall TS, Olino K. Palliative Care for Pancreatic and Periampullary Cancer. Surg Clin North Am 2016;96:1415-30. [PMID: 27865285 DOI: 10.1016/j.suc.2016.07.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
76 Li D, O'Reilly EM. Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma. Semin Oncol 2015;42:134-43. [PMID: 25726058 DOI: 10.1053/j.seminoncol.2014.12.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
77 Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Annals of Surgery 2018;268:610-9. [DOI: 10.1097/sla.0000000000002957] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
78 Bahrami A, Khazaei M, Bagherieh F, Ghayour-Mobarhan M, Maftouh M, Hassanian SM, Avan A. Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies. J Cell Physiol. 2017;232:2931-2937. [PMID: 28083912 DOI: 10.1002/jcp.25798] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
79 Lavu H, Yeo CJ. Pancreatic ductal adenocarcinoma treatment--the past, present, and future. Semin Oncol. 2015;42:4-7. [PMID: 25726047 DOI: 10.1053/j.seminoncol.2014.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019;68:742-58. [PMID: 30396902 DOI: 10.1136/gutjnl-2018-316822] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
81 Chen X, Tian J, Su GH, Lin J. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells. Curr Cancer Drug Targets 2019;19:417-27. [PMID: 29714141 DOI: 10.2174/1568009618666180430123939] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
82 Taboada AGM, Lominchar PL, Roman LM, García-Alfonso P, Martin AJM, Rodriguez JAB, Pascual JMA. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. Ann Hepatobiliary Pancreat Surg 2021;25:179-91. [PMID: 34053920 DOI: 10.14701/ahbps.2021.25.2.179] [Reference Citation Analysis]
83 Fathi A, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Johnston FM, Evans DB, Tsai S. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. J Gastrointest Oncol. 2015;6:418-429. [PMID: 26261728 DOI: 10.3978/j.issn.2078-6891.2015.053] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
84 Epelboym I, Zenati MS, Hamad A, Steve J, Lee KK, Bahary N, Hogg ME, Zeh HJ, Zureikat AH. Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival. Ann Surg Oncol 2017;24:2744-51. [DOI: 10.1245/s10434-017-5975-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
85 Borazanci E, Sckolnik S, Amini A. Neo-adjuvant therapy for pancreatic cancer: hope for the future. Expert Rev Gastroenterol Hepatol 2019;13:579-89. [PMID: 30979348 DOI: 10.1080/17474124.2019.1607294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
86 Dudeja V, Livingstone A. Is age just a number: pancreaticoduodenectomy in elderly patients? Hepatobiliary & Pancreatic Diseases International 2016;15:346-7. [DOI: 10.1016/s1499-3872(16)60108-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Bradley A, Van Der Meer R. Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis. Sci Rep 2019;9:4354. [PMID: 30867522 DOI: 10.1038/s41598-019-40951-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 10.5] [Reference Citation Analysis]
88 Li Y, Zhao Z, Lin CY, Liu Y, Staveley-OCarroll KF, Li G, Cheng K. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer. Theranostics 2021;11:2182-200. [PMID: 33500719 DOI: 10.7150/thno.53102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
89 van Dongen JC, Smits FJ, van Santvoort HC, Molenaar IQ, Busch OR, Besselink MG, Aziz MH, Groot Koerkamp B, van Eijck CH. C-reactive protein is superior to white blood cell count for early detection of complications after pancreatoduodenectomy: a retrospective multicenter cohort study. HPB 2020;22:1504-12. [DOI: 10.1016/j.hpb.2020.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
90 Ielpo B. The issue of how predict survival of patients affected by locally advanced pancreatic cancer. Ann Transl Med 2018;6:S128. [PMID: 30740449 DOI: 10.21037/atm.2018.12.41] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Allen PJ, Kuk D, Castillo CF, Basturk O, Wolfgang CL, Cameron JL, Lillemoe KD, Ferrone CR, Morales-Oyarvide V, He J, Weiss MJ, Hruban RH, Gönen M, Klimstra DS, Mino-Kenudson M. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. Ann Surg 2017;265:185-91. [PMID: 27163957 DOI: 10.1097/SLA.0000000000001763] [Cited by in Crossref: 217] [Cited by in F6Publishing: 98] [Article Influence: 54.3] [Reference Citation Analysis]
92 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 94] [Article Influence: 19.4] [Reference Citation Analysis]
93 Bronsert P, Kohler I, Timme S, Kiefer S, Werner M, Schilling O, Vashist Y, Makowiec F, Brabletz T, Hopt UT. Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer. Surgery. 2014;156:97-108. [PMID: 24929761 DOI: 10.1016/j.surg.2014.02.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 6.7] [Reference Citation Analysis]
94 Yi JM, Guzzetta AA, Bailey VJ, Downing SR, Van Neste L, Chiappinelli KB, Keeley BP, Stark A, Herrera A, Wolfgang C. Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res. 2013;19:6544-6555. [PMID: 24088737 DOI: 10.1158/1078-0432.ccr-12-3224] [Cited by in Crossref: 84] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
95 Mielgo A, Schmid MC. Impact of tumour associated macrophages in pancreatic cancer. BMB Rep 2013;46:131-8. [PMID: 23527856 DOI: 10.5483/bmbrep.2013.46.3.036] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 6.8] [Reference Citation Analysis]
96 Michalski CW, Kong B, Jäger C, Kloe S, Beier B, Braren R, Esposito I, Erkan M, Friess H, Kleeff J. Outcomes of resections for pancreatic adenocarcinoma with suspected venous involvement: a single center experience. BMC Surg 2015;15:100. [PMID: 26296752 DOI: 10.1186/s12893-015-0086-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
97 Coe TM, Fong ZV, Wilson SE, Talamini MA, Lillemoe KD, Chang DC. Outcomes Improvement Is Not Continuous Along the Learning Curve for Pancreaticoduodenectomy at the Hospital Level. J Gastrointest Surg 2015;19:2132-7. [PMID: 26438484 DOI: 10.1007/s11605-015-2967-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
98 Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9:454-467. [PMID: 22710569 DOI: 10.1038/nrgastro.2012.115] [Cited by in Crossref: 353] [Cited by in F6Publishing: 322] [Article Influence: 39.2] [Reference Citation Analysis]
99 Nakamoto M, Matsuyama A, Shiba E, Shibuya R, Kasai T, Yamaguchi K, Hisaoka M. Prognostic significance of WNT signaling in pancreatic ductal adenocarcinoma. Virchows Arch 2014;465:401-8. [PMID: 25146168 DOI: 10.1007/s00428-014-1642-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
100 Chen S, Chen JZ, Zhan Q, Deng XX, Shen BY, Peng CH, Li HW. Robot-assisted laparoscopic versus open pancreaticoduodenectomy: a prospective, matched, mid-term follow-up study. Surg Endosc. 2015;29:3698-3711. [PMID: 25761559 DOI: 10.1007/s00464-015-4140-y] [Cited by in Crossref: 105] [Cited by in F6Publishing: 83] [Article Influence: 17.5] [Reference Citation Analysis]
101 Liu Y, Awadia S, Delaney A, Sitto M, Engelke CG, Patel H, Calcaterra A, Zelenka-Wang S, Lee H, Contessa J, Neamati N, Ljungman M, Lawrence TS, Morgan MA, Rehemtulla A. UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer. Transl Oncol 2020;13:100834. [PMID: 32688248 DOI: 10.1016/j.tranon.2020.100834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
102 Nussbaum DP, Adam MA, Youngwirth LM, Ganapathi AM, Roman SA, Tyler DS, Sosa JA, Blazer DG 3rd. Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma. Ann Surg Oncol. 2016;23:1026-1033. [PMID: 26542590 DOI: 10.1245/s10434-015-4937-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
103 Winter JM, Tang LH, Klimstra DS, Liu W, Linkov I, Brennan MF, D’Angelica MI, DeMatteo RP, Fong Y, Jarnagin WR. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. Ann Surg. 2013;258:331-335. [PMID: 23360922 DOI: 10.1097/sla.0b013e31827fe9ce] [Cited by in Crossref: 51] [Cited by in F6Publishing: 20] [Article Influence: 6.4] [Reference Citation Analysis]
104 Barnes AF, Yeo TP, Leiby B, Kay A, Winter JM. Pancreatic Cancer–Associated Depression: A Case Report and Review of the Literature. Pancreas 2018;47:1065-77. [DOI: 10.1097/mpa.0000000000001148] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
105 Morimoto D, Yamada S, Murotani K, Sonohara F, Takami H, Suenaga M, Hayashi M, Niwa Y, Tashiro M, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y. Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification. Pancreas 2018;47:1350-6. [PMID: 30286011 DOI: 10.1097/MPA.0000000000001186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
106 Chakraborty J, Langdon-Embry L, Cunanan KM, Escalon JG, Allen PJ, Lowery MA, O'Reilly EM, Gönen M, Do RG, Simpson AL. Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. PLoS One 2017;12:e0188022. [PMID: 29216209 DOI: 10.1371/journal.pone.0188022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
107 Ielpo B, Duran H, Diaz E, Fabra I, Caruso R, Ferri V, Malavé L, Hidalgo M, Alvarez R, Plaza C, Quijano Y, Vicente E. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Eur J Surg Oncol 2016;42:1394-400. [PMID: 26899943 DOI: 10.1016/j.ejso.2016.01.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 8.2] [Reference Citation Analysis]
108 Ahmad E, Ali A, Fatima MT, Nimisha, Apurva, Kumar A, Sumi MP, Sattar RSA, Mahajan B, Saluja SS. Ligand decorated biodegradable nanomedicine in the treatment of cancer. Pharmacol Res 2021;167:105544. [PMID: 33722711 DOI: 10.1016/j.phrs.2021.105544] [Reference Citation Analysis]
109 Li G, Chen JZ, Chen S, Lin SZ, Pan W, Meng ZW, Cai XR, Chen YL. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma. Cancer Med 2020;9:3353-70. [PMID: 32181599 DOI: 10.1002/cam4.2959] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
110 Schiffman SC, Abberbock S, Winters S, Valko C, Steve J, Zureikat AH, Zeh HJ, Hogg ME. A pancreatic cancer multidisciplinary clinic: insights and outcomes. Journal of Surgical Research 2016;202:246-52. [DOI: 10.1016/j.jss.2016.01.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
111 Maulat C, Canivet C, Touraine C, Gourgou S, Napoleon B, Palazzo L, Flori N, Piessen G, Guibert P, Truant S, Assenat E, Buscail L, Bournet B, Muscari F, The Bacap Consortium. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Cancers (Basel) 2020;12:E783. [PMID: 32218346 DOI: 10.3390/cancers12040783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
112 King JC, Zenati M, Steve J, Winters SB, Bartlett DL, Zureikat AH, Zeh HJ 3rd, Hogg ME. Deviations from Expected Treatment of Pancreatic Cancer in Octogenarians: Analysis of Patient and Surgeon Factors. Ann Surg Oncol 2016;23:4149-55. [PMID: 27459986 DOI: 10.1245/s10434-016-5456-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
113 Zhong Y, Macgregor-Das A, Saunders T, Whittle MC, Makohon-Moore A, Kohutek ZA, Poling J, Herbst BT, Javier BM, Cope L, Leach SD, Hingorani SR, Iacobuzio-Donahue CA. Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Clin Cancer Res 2017;23:1607-20. [PMID: 27637888 DOI: 10.1158/1078-0432.CCR-15-1615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
114 Erkan M, Brocks T, Friess H. The Role of Non-cancerous Cells in Cancer: Pancreatic Ductal Adenocarcinoma as a Model to Understand the Impact of Tumor Microenvironment on Epithelial Carcinogenesis. In: Bae YH, Mrsny RJ, Park K, editors. Cancer Targeted Drug Delivery. New York: Springer; 2013. pp. 309-33. [DOI: 10.1007/978-1-4614-7876-8_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
115 Covantev S, Mazuruc N, Belic O. The Arterial Supply of the Distal Part of the Pancreas. Surg Res Pract. 2019;2019:5804047. [PMID: 31016226 DOI: 10.1155/2019/5804047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
116 Boevers E, McDowell BD, Mott SL, Button AM, Lynch CF. Insurance Status Is Related to Receipt of Therapy and Survival in Patients with Early-Stage Pancreatic Exocrine Carcinoma. J Cancer Epidemiol 2017;2017:4354592. [PMID: 28487737 DOI: 10.1155/2017/4354592] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
117 Choi JI, Jang SI, Hong J, Kim CH, Kwon SS, Park JS, Lim JB. Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells. Cancer Lett 2021;498:42-53. [PMID: 33188841 DOI: 10.1016/j.canlet.2020.10.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
118 Araujo-Gutierrez R, Van Eps JL, Kirui D, Bryan NS, Kang Y, Fleming JB, Fernandez-Moure JS. Enhancement of gemcitabine cytotoxicity in pancreatic adenocarcinoma through controlled release of nitric oxide. Biomed Microdevices 2019;21:23. [PMID: 30790060 DOI: 10.1007/s10544-019-0375-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Coleman O, Henry M, McVey G, Clynes M, Moriarty M, Meleady P. Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact. Expert Rev Proteomics 2016;13:383-94. [PMID: 26985644 DOI: 10.1586/14789450.2016.1167601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
120 Petermann D, Demartines N, Schäfer M. Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head? HPB (Oxford). 2013;15:872-881. [PMID: 23458601 DOI: 10.1111/hpb.12052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
121 Johnson MD, Stone B, Thibodeau BJ, Baschnagel AM, Galoforo S, Fortier LE, Ketelsen B, Ahmed S, Kelley Z, Hana A, Wilson TG, Robertson JM, Jury RP, Wilson GD. The significance of Trk receptors in pancreatic cancer. Tumour Biol 2017;39:1010428317692256. [PMID: 28218045 DOI: 10.1177/1010428317692256] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
122 Klaiber U, Schnaidt ES, Hinz U, Gaida MM, Heger U, Hank T, Strobel O, Neoptolemos JP, Mihaljevic AL, Büchler MW, Hackert T. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. Ann Surg 2021;273:154-62. [PMID: 30921051 DOI: 10.1097/SLA.0000000000003270] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 32.0] [Reference Citation Analysis]
123 Hattori N, Yamada S, Torii K, Takeda S, Nakamura K, Tanaka H, Kajiyama H, Kanda M, Fujii T, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Mizuno M, Hori M, Kodera Y. Effectiveness of plasma treatment on pancreatic cancer cells. Int J Oncol 2015;47:1655-62. [PMID: 26351772 DOI: 10.3892/ijo.2015.3149] [Cited by in Crossref: 72] [Cited by in F6Publishing: 53] [Article Influence: 12.0] [Reference Citation Analysis]
124 Perinel J, Adham M. Palliative therapy in pancreatic cancer-palliative surgery. Transl Gastroenterol Hepatol 2019;4:28. [PMID: 31231695 DOI: 10.21037/tgh.2019.04.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
125 Sandhu V, Labori KJ, Borgida A, Lungu I, Bartlett J, Hafezi-bakhtiari S, Denroche RE, Jang GH, Pasternack D, Mbaabali F, Watson M, Wilson J, Kure EH, Gallinger S, Haibe-kains B. Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma. JCO Clinical Cancer Informatics 2019. [DOI: 10.1200/cci.18.00102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
126 Wang X, Chung WY, Correa E, Zhu Y, Issa E, Dennison AR. The integration of artificial intelligence models to augment imaging modalities in pancreatic cancer. Journal of Pancreatology 2020;3:173-80. [DOI: 10.1097/jp9.0000000000000056] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Zhu W, Wang Y, Zhang D, Yu X, Leng X. MiR-7-5p functions as a tumor suppressor by targeting SOX18 in pancreatic ductal adenocarcinoma. Biochemical and Biophysical Research Communications 2018;497:963-70. [DOI: 10.1016/j.bbrc.2018.02.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
128 Iacobuzio-donahue CA, Litchfield K, Swanton C. Intratumor heterogeneity reflects clinical disease course. Nat Cancer 2020;1:3-6. [DOI: 10.1038/s43018-019-0002-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 20.0] [Reference Citation Analysis]
129 Luo X, Liu J, Wang H, Lu H. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis. Pharmacol Res 2020;156:104805. [PMID: 32278036 DOI: 10.1016/j.phrs.2020.104805] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
130 Zureikat AH, Hogg ME, Zeh HJ. The Utility of the Robot in Pancreatic Resections. Advances in Surgery 2014;48:77-95. [DOI: 10.1016/j.yasu.2014.05.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
131 Jung JP, Zenati MS, Dhir M, Zureikat AH, Zeh HJ, Simmons RL, Hogg ME. Use of Video Review to Investigate Technical Factors That May Be Associated With Delayed Gastric Emptying After Pancreaticoduodenectomy. JAMA Surg 2018;153:918-27. [PMID: 29998288 DOI: 10.1001/jamasurg.2018.2089] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
132 Dudekula A, Munigala S, Zureikat AH, Yadav D. Operative Trends for Pancreatic Diseases in the USA: Analysis of the Nationwide Inpatient Sample from 1998-2011. J Gastrointest Surg 2016;20:803-11. [PMID: 26791389 DOI: 10.1007/s11605-015-3067-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
133 Shi YJ, Li XT, Zhang XY, Zhu HT, Liu YL, Wei YY, Sun YS. Non-gaussian models of 3-Tesla diffusion-weighted MRI for the differentiation of pancreatic ductal adenocarcinomas from neuroendocrine tumors and solid pseudopapillary neoplasms. Magn Reson Imaging 2021;83:68-76. [PMID: 34314825 DOI: 10.1016/j.mri.2021.07.006] [Reference Citation Analysis]
134 Grapa CM, Mocan L, Crisan D, Florea M, Mocan T. Biomarkers in Pancreatic Cancer as Analytic Targets for Nanomediated Imaging and Therapy. Materials (Basel) 2021;14:3083. [PMID: 34199998 DOI: 10.3390/ma14113083] [Reference Citation Analysis]
135 Baig MS, Roy A, Rajpoot S, Liu D, Savai R, Banerjee S, Kawada M, Faisal SM, Saluja R, Saqib U, Ohishi T, Wary KK. Tumor-derived exosomes in the regulation of macrophage polarization. Inflamm Res 2020;69:435-51. [DOI: 10.1007/s00011-020-01318-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 32.0] [Reference Citation Analysis]
136 Pak LM, Gonen M, Seier K, Balachandran VP, D'Angelica MI, Jarnagin WR, Kingham TP, Allen PJ, Do RKG, Simpson AL. Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? Abdom Radiol (NY) 2018;43:2113-8. [PMID: 29177926 DOI: 10.1007/s00261-017-1407-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Krepline AN, Christians KK, Duelge K, Mahmoud A, Ritch P, George B, Erickson BA, Foley WD, Quebbeman EJ, Turaga KK, Johnston FM, Gamblin TC, Evans DB, Tsai S. Patency Rates of Portal Vein/Superior Mesenteric Vein Reconstruction After Pancreatectomy for Pancreatic Cancer. J Gastrointest Surg 2014;18:2016-25. [DOI: 10.1007/s11605-014-2635-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
138 Ward EP, Evans DB, Tsai S. Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective. J Surg Oncol 2021;123:1405-13. [PMID: 33831252 DOI: 10.1002/jso.26395] [Reference Citation Analysis]
139 Hitchcock KE, Nichols RC, Morris CG, Bose D, Hughes SJ, Stauffer JA, Celinski SA, Johnson EA, Zaiden RA, Mendenhall NP, Rutenberg MS. Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. World J Gastrointest Surg. 2017;9:103-108. [PMID: 28503258 DOI: 10.4240/wjgs.v9.i4.103] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
140 Evans DB, Ritch PS, Erickson BA. Neoadjuvant Therapy for Localized Pancreatic Cancer: Support Is Growing? Annals of Surgery 2015;261:18-20. [DOI: 10.1097/sla.0000000000000996] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 3.2] [Reference Citation Analysis]
141 Peng J, Liu L, Huang D, Chen H, Dai M, Guo J, Zhang T, Liao Q, Jiang J, Wang W, Guo D, Cao D, Xuan Z, Li D, Zhao Y, Wu W. Impact of ischemia on sample quality of human pancreatic tissues. Pancreatology 2020;20:265-77. [PMID: 31956070 DOI: 10.1016/j.pan.2019.11.005] [Reference Citation Analysis]
142 Tzeng CD, Cao HST, Lee JE, Pisters PWT, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey J, Aloia TA, Fleming JB, Katz MHG. Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival. J Gastrointest Surg 2014;18:16-25. [DOI: 10.1007/s11605-013-2412-1] [Cited by in Crossref: 121] [Cited by in F6Publishing: 105] [Article Influence: 15.1] [Reference Citation Analysis]
143 Zheng B, Qu J, Ohuchida K, Feng H, Chong SJF, Yan Z, Piao Y, Liu P, Sheng N, Eguchi D, Ohtsuka T, Mizumoto K, Liu Z, Pervaiz S, Gong P, Nakamura M. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer. Theranostics 2020;10:10274-89. [PMID: 32929348 DOI: 10.7150/thno.47001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
144 de Wilde RF, Besselink MG, van der Tweel I, de Hingh IH, van Eijck CH, Dejong CH, Porte RJ, Gouma DJ, Busch OR, Molenaar IQ; Dutch Pancreatic Cancer Group. Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg. 2012;99:404-410. [PMID: 22237731 DOI: 10.1002/bjs.8664] [Cited by in Crossref: 201] [Cited by in F6Publishing: 166] [Article Influence: 22.3] [Reference Citation Analysis]
145 Tam V, Zenati M, Novak S, Chen Y, Zureikat AH, Zeh HJ 3rd, Hogg ME. Robotic Pancreatoduodenectomy Biotissue Curriculum has Validity and Improves Technical Performance for Surgical Oncology Fellows.J Surg Educ. 2017;74:1057-1065. [PMID: 28578981 DOI: 10.1016/j.jsurg.2017.05.016] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 11.3] [Reference Citation Analysis]
146 Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, Rocha FG, Jia X, Qin LX, D'Angelica MI, DeMatteo RP, Fong Y, Jarnagin WR, O'Reilly EM, Allen PJ. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One 2012;7:e40157. [PMID: 22792233 DOI: 10.1371/journal.pone.0040157] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 8.1] [Reference Citation Analysis]
147 Ng KYY, Chow EWX, Jiang B, Lim C, Goh BKP, Lee SY, Teo JY, Tan DMY, Cheow PC, Ooi LLPJ, Chow PKH, Lee JJX, Kam JH, Koh YX, Jeyaraj PR, Tan EK, Choo SP, Chan CY, Chung AYF, Tai D. Resected pancreatic adenocarcinoma: An Asian institution's experience. Cancer Rep (Hoboken) 2021;:e1393. [PMID: 33939335 DOI: 10.1002/cnr2.1393] [Reference Citation Analysis]
148 Binziad S, Salem AA, Amira G, Mourad F, Ibrahim AK, Manim TM. Impact of reconstruction methods and pathological factors on survival after pancreaticoduodenectomy. South Asian J Cancer 2013;2:160-8. [PMID: 24455609 DOI: 10.4103/2278-330X.114145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
149 Ammori JB, Choong K, Hardacre JM. Surgical Therapy for Pancreatic and Periampullary Cancer. Surg Clin North Am. 2016;96:1271-1286. [PMID: 27865277 DOI: 10.1016/j.suc.2016.07.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
150 Park HM, Park SJ, Han SS, Kim SH. Surgery for elderly patients with resectable pancreatic cancer, a comparison with non-surgical treatments: a retrospective study outcomes of resectable pancreatic cancer. BMC Cancer 2019;19:1090. [PMID: 31718565 DOI: 10.1186/s12885-019-6255-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
151 Muaddi H, Karanicolas PJ. Postoperative pancreatic fistula: Still the Achilles' heel of pancreatic surgery. Surgery 2021;169:1454-5. [PMID: 33750597 DOI: 10.1016/j.surg.2021.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Nichols RC, Huh S, Li Z, Rutenberg M. Proton therapy for pancreatic cancer. World J Gastrointest Oncol 2015;7:141-7. [PMID: 26380057 DOI: 10.4251/wjgo.v7.i9.141] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
153 Lewis R, Drebin JA, Callery MP, Fraker D, Kent TS, Gates J, Vollmer CM. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford). 2013;15:49-60. [PMID: 23216779 DOI: 10.1111/j.1477-2574.2012.00571.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 8.0] [Reference Citation Analysis]
154 Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017;21:164-174. [PMID: 27778257 DOI: 10.1007/s11605-016-3265-1] [Cited by in Crossref: 92] [Cited by in F6Publishing: 73] [Article Influence: 18.4] [Reference Citation Analysis]
155 Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH, Campbell F, Valle JW, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ting Y, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Lerch MM, Mayerle J, Tjaden C, Strobel O, Hackert T, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surg 2019;154:1038-48. [PMID: 31483448 DOI: 10.1001/jamasurg.2019.3337] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 45.0] [Reference Citation Analysis]
156 Kasahara N, Noda H, Kakizawa N, Kato T, Watanabe F, Ichida K, Endo Y, Aizawa H, Rikiyama T. A lack of postoperative complications after pancreatectomy contributes to the long-term survival of patients with pancreatic cancer. Pancreatology 2019;19:686-94. [PMID: 31253497 DOI: 10.1016/j.pan.2019.06.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
157 Wu ST, Fowler AJ, Garmon CB, Fessler AB, Ogle JD, Grover KR, Allen BC, Williams CD, Zhou R, Yazdanifar M, Ogle CA, Mukherjee P. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles. BMC Cancer 2018;18:457. [PMID: 29685122 DOI: 10.1186/s12885-018-4393-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
158 Alabd A, Alabd A, Bolaji O, Sugumar K, Ammori J, Hardacre J, Winter JM. Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC). Ann Surg Oncol 2021;28:1060-8. [PMID: 32968957 DOI: 10.1245/s10434-020-08859-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Caso R, Miller G. Role of tumor associated macrophages in regulating pancreatic cancer progression. WJI 2016;6:9. [DOI: 10.5411/wji.v6.i1.9] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
160 Bradley A, Van Der Meer R, McKay CJ. A systematic review of methodological quality of model development studies predicting prognostic outcome for resectable pancreatic cancer. BMJ Open 2019;9:e027192. [PMID: 31439598 DOI: 10.1136/bmjopen-2018-027192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
161 Chronopoulos A, Robinson B, Sarper M, Cortes E, Auernheimer V, Lachowski D, Attwood S, García R, Ghassemi S, Fabry B, Del Río Hernández A. ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion. Nat Commun 2016;7:12630. [PMID: 27600527 DOI: 10.1038/ncomms12630] [Cited by in Crossref: 121] [Cited by in F6Publishing: 111] [Article Influence: 24.2] [Reference Citation Analysis]
162 Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH. Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas. Mol Oncol 2015;9:758-71. [PMID: 25579086 DOI: 10.1016/j.molonc.2014.12.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
163 Hausmann S, Kong B, Michalski C, Erkan M, Friess H. The role of inflammation in pancreatic cancer. Adv Exp Med Biol. 2014;816:129-151. [PMID: 24818722 DOI: 10.1007/978-3-0348-0837-8_6] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 7.4] [Reference Citation Analysis]
164 Oneda E, Zaniboni A. Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature. J Clin Med 2019;8:E1922. [PMID: 31717439 DOI: 10.3390/jcm8111922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
165 Girgis MD, Zenati MS, King JC, Hamad A, Zureikat AH, Zeh HJ, Hogg ME. Oncologic Outcomes After Robotic Pancreatic Resections Are Not Inferior to Open Surgery. Ann Surg. 2019;. [PMID: 31663967 DOI: 10.1097/sla.0000000000003615] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 10.5] [Reference Citation Analysis]
166 Kumar D, Sharma P, Singh H, Nepali K, Gupta GK, Jain SK, Ntie-kang F. The value of pyrans as anticancer scaffolds in medicinal chemistry. RSC Adv 2017;7:36977-99. [DOI: 10.1039/c7ra05441f] [Cited by in Crossref: 83] [Cited by in F6Publishing: 2] [Article Influence: 20.8] [Reference Citation Analysis]
167 Tsai S, Erickson BA, Dua K, Ritch PS, Tolat P, Evans DB. Evolution of the Management of Resectable Pancreatic Cancer. JOP 2016;12:772-8. [DOI: 10.1200/jop.2016.015818] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
168 Függer R, Gangl O, Fröschl U. Clinical approach to the patient with a solid pancreatic mass. Wien Med Wochenschr 2014;164:73-9. [PMID: 24577681 DOI: 10.1007/s10354-014-0266-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
169 Toomey PG, Vohra NA, Ghansah T, Sarnaik AA, Pilon-Thomas SA. Immunotherapy for gastrointestinal malignancies. Cancer Control 2013;20:32-42. [PMID: 23302905 DOI: 10.1177/107327481302000106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
170 Weniger M, Miksch RC, Maisonneuve P, Werner J, D'haese JG. Improvement of survival after surgical resection of pancreatic cancer independent of adjuvant chemotherapy in the past two decades – A meta-regression. European Journal of Surgical Oncology 2020;46:1516-23. [DOI: 10.1016/j.ejso.2020.02.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
171 Kohler I, Bronsert P, Timme S, Werner M, Brabletz T, Hopt UT, Schilling O, Bausch D, Keck T, Wellner UF. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol. 2015;30 Suppl 1:78-84. [PMID: 25827809 DOI: 10.1111/jgh.12752] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
172 Lachowski D, Cortes E, Pink D, Chronopoulos A, Karim SA, P Morton J, Del Río Hernández AE. Substrate Rigidity Controls Activation and Durotaxis in Pancreatic Stellate Cells. Sci Rep 2017;7:2506. [PMID: 28566691 DOI: 10.1038/s41598-017-02689-x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 14.8] [Reference Citation Analysis]
173 Basturk O, Saka B, Balci S, Postlewait LM, Knight J, Goodman M, Kooby D, Sarmiento JM, El-Rayes B, Choi H, Bagci P, Krasinskas A, Quigley B, Reid MD, Akkas G, Maithel SK, Adsay V. Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM Staging. Ann Surg Oncol. 2015;22 Suppl 3:S1187-S1195. [PMID: 26362048 DOI: 10.1245/s10434-015-4861-0] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 9.5] [Reference Citation Analysis]
174 Chen XP, Liu J, Zhou J, Zhou PC, Shu J, Xu LL, Li B, Su S. Combination of CEUS and MRI for the diagnosis of periampullary space-occupying lesions: a retrospective analysis. BMC Med Imaging 2019;19:77. [PMID: 31477041 DOI: 10.1186/s12880-019-0376-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 Gao S, Zhu X, Shi X, Cao K, Bian Y, Jiang H, Wang K, Guo S, Zhang H, Jin G. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Radiat Oncol 2019;14:52. [PMID: 30917842 DOI: 10.1186/s13014-019-1254-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
176 Bradley A, Van Der Meer R. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis. PLoS One 2019;14:e0212805. [PMID: 30817807 DOI: 10.1371/journal.pone.0212805] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
177 Kamarajah SK, Sonnenday CJ, Cho CS, Frankel TL, Bednar F, Lawrence TS, Nathan H. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis. Annals of Surgery 2021;273:587-94. [DOI: 10.1097/sla.0000000000003242] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
178 Kamarajah SK, Bundred JR, Alrawashdeh W, Manas D, White SA. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC).HPB (Oxford). 2020;22:649-659. [PMID: 31894014 DOI: 10.1016/j.hpb.2019.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
179 McIntyre CA, Winter JM. Diagnostic evaluation and staging of pancreatic ductal adenocarcinoma. Semin Oncol 2015;42:19-27. [PMID: 25726049 DOI: 10.1053/j.seminoncol.2014.12.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
180 Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A, Williams T, Abushahin L, Bridges JFP, Santry H. Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2020;9. [PMID: 32326559 DOI: 10.3390/jcm9041129] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 24.0] [Reference Citation Analysis]
181 Clancy TE. Surgery for Pancreatic Cancer. Hematol Oncol Clin North Am 2015;29:701-16. [PMID: 26226905 DOI: 10.1016/j.hoc.2015.04.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
182 Cherkassky L, Jarnagin W. Selecting treatment sequence for patients with incidental gallbladder cancer: a neoadjuvant approach versus upfront surgery. Updates Surg 2019;71:217-25. [PMID: 31254234 DOI: 10.1007/s13304-019-00670-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
183 Miller-ocuin JL, Zenati MS, Ocuin LM, Varley PR, Novak SM, Winters S, Zureikat AH, Zeh HJ, Hogg ME. Failure to Treat: Audit of an Institutional Cancer Registry Database at a Large Comprehensive Cancer Center Reveals Factors Affecting the Treatment of Pancreatic Cancer. Ann Surg Oncol 2017;24:2387-96. [DOI: 10.1245/s10434-017-5880-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
184 McDowell BD, Chapman CG, Smith BJ, Button AM, Chrischilles EA, Mezhir JJ. Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis. Ann Surg. 2015;261:740-745. [PMID: 24979599 DOI: 10.1097/sla.0000000000000796] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
185 Sanford DE, Sanford AM, Fields RC, Hawkins WG, Strasberg SM, Linehan DC. Severe nutritional risk predicts decreased long-term survival in geriatric patients undergoing pancreaticoduodenectomy for benign disease. J Am Coll Surg 2014;219:1149-56. [PMID: 25442378 DOI: 10.1016/j.jamcollsurg.2014.06.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
186 Zureikat AH, Borrebach J, Pitt HA, Mcgill D, Hogg ME, Thompson V, Bentrem DJ, Hall BL, Zeh HJ. Minimally invasive hepatopancreatobiliary surgery in North America: an ACS-NSQIP analysis of predictors of conversion for laparoscopic and robotic pancreatectomy and hepatectomy. HPB (Oxford) 2017;19:595-602. [PMID: 28400087 DOI: 10.1016/j.hpb.2017.03.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
187 Vega EA, Kutlu OC, Salehi O, James D, Alarcon SV, Herrick B, Krishnan S, Kozyreva O, Conrad C. Preoperative Chemotherapy for Pancreatic Cancer Improves Survival and R0 Rate Even in Early Stage I. J Gastrointest Surg. 2020;24:2409-2415. [PMID: 32394126 DOI: 10.1007/s11605-020-04601-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
188 Place TL, Nau P, Mezhir JJ. Minimally invasive pancreatectomy for cancer: a critical review of the current literature. J Gastrointest Surg. 2015;19:375-386. [PMID: 25389057 DOI: 10.1007/s11605-014-2695-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
189 Lewis S, Sastri SC, Arya S, Mehta S, Patil P, Shrivastava S, Phurailatpam R, Shrikhande SV, Engineer R. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study. J Gastrointest Oncol 2019;10:474-82. [PMID: 31183197 DOI: 10.21037/jgo.2019.01.25] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
190 Plichta JK, Godambe AS, Fridirici Z, Yong S, Sinacore JM, Abood GJ, Aranha GV. The Association between Survival and the Pathologic Features of Periampullary Tumors Varies over Time. HPB Surg 2014;2014:890530. [PMID: 25104878 DOI: 10.1155/2014/890530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
191 Deobald RG, Cheng ES, Ko YJ, Wright FC, Karanicolas PJ. A qualitative study of patient and clinician attitudes regarding surveillance after a resection of pancreatic and peri-ampullary cancer. HPB (Oxford) 2015;17:409-15. [PMID: 25545219 DOI: 10.1111/hpb.12378] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
192 Shridhar R, Takahashi C, Huston J, Meredith KL. Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis. J Gastrointest Oncol 2019;10:663-73. [PMID: 31392047 DOI: 10.21037/jgo.2019.02.09] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
193 Sohal DP, Walsh RM, Ramanathan RK, Khorana AA. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106:dju011. [PMID: 24563516 DOI: 10.1093/jnci/dju011] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 12.0] [Reference Citation Analysis]
194 Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016;16:553-565. [PMID: 27444064 DOI: 10.1038/nrc.2016.66] [Cited by in Crossref: 183] [Cited by in F6Publishing: 158] [Article Influence: 36.6] [Reference Citation Analysis]
195 Dupré A, Melodelima D, Pflieger H, Chen Y, Vincenot J, Kocot A, Langonnet S, Rivoire M. Thermal Ablation of the Pancreas With Intraoperative High-Intensity Focused Ultrasound: Safety and Efficacy in a Porcine Model. Pancreas 2017;46:219-24. [DOI: 10.1097/mpa.0000000000000720] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
196 Yamao T, Yamashita YI, Yamamura K, Nakao Y, Tsukamoto M, Nakagawa S, Okabe H, Hayashi H, Imai K, Baba H. Cellular Senescence, Represented by Expression of Caveolin-1, in Cancer-Associated Fibroblasts Promotes Tumor Invasion in Pancreatic Cancer. Ann Surg Oncol 2019;26:1552-9. [PMID: 30805811 DOI: 10.1245/s10434-019-07266-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
197 Altman AM, Wirth K, Marmor S, Lou E, Chang K, Hui JYC, Tuttle TM, Jensen EH, Denbo JW. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival. Ann Surg Oncol. 2019;26:4108-4116. [PMID: 31313044 DOI: 10.1245/s10434-019-07602-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 15.5] [Reference Citation Analysis]
198 Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA, Cvancarova M, Edwin B, Kure EH, Eide TJ, Dueland S, Buanes T, Gladhaug IP. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – A population-based cohort study. Acta Oncologica 2016;55:265-77. [DOI: 10.3109/0284186x.2015.1068445] [Cited by in Crossref: 67] [Cited by in F6Publishing: 27] [Article Influence: 11.2] [Reference Citation Analysis]
199 Khalil A, Ewald J, Marchese U, Autret A, Garnier J, Niccoli P, Piana G, Poizat F, Giovannini M, Delpero JR, Turrini O. A single-center experience with pancreatic cystic neuroendocrine tumors. World J Surg Oncol 2020;18:208. [PMID: 32799893 DOI: 10.1186/s12957-020-01994-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Holst S, Belo AI, Giovannetti E, van Die I, Wuhrer M. Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation. Sci Rep. 2017;7:16623. [PMID: 29192278 DOI: 10.1038/s41598-017-16811-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
201 Zureikat AH, Moser AJ, Boone BA, Bartlett DL, Zenati M, Zeh HJ. 250 robotic pancreatic resections: safety and feasibility. Ann Surg. 2013;258:554-559; discussion 559-562. [PMID: 24002300 DOI: 10.1097/sla.0b013e3182a4e87c] [Cited by in Crossref: 232] [Cited by in F6Publishing: 76] [Article Influence: 29.0] [Reference Citation Analysis]
202 O’Reilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, Tang LH, LaValle J, Winston C, DeMatteo RP. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260:142-148. [PMID: 24901360 DOI: 10.1097/sla.0000000000000251] [Cited by in Crossref: 92] [Cited by in F6Publishing: 37] [Article Influence: 13.1] [Reference Citation Analysis]
203 Barugola G, Partelli S, Crippa S, Butturini G, Salvia R, Sartori N, Bassi C, Falconi M, Pederzoli P. Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre. HPB (Oxford). 2013;15:958-964. [PMID: 23490217 DOI: 10.1111/hpb.12073] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
204 Clark W, Silva M, Donn N, Luberice K, Humphries LA, Paul H, Hernandez J, Ross SB, Rosemurgy A. Targeting Early Deaths Following Pancreaticoduodenectomy to Improve Survival. J Gastrointest Surg 2012;16:1869-74. [DOI: 10.1007/s11605-012-1958-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
205 Sallinen V, Le Large TY, Galeev S, Kovalenko Z, Tieftrunk E, Araujo R, Ceyhan GO, Gaujoux S. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors - a systematic review and meta-analysis. HPB (Oxford). 2017;19:310-320. [PMID: 28254159 DOI: 10.1016/j.hpb.2016.12.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 10.8] [Reference Citation Analysis]
206 Erkan M, Hausmann S, Michalski CW, Schlitter AM, Fingerle AA, Dobritz M, Friess H, Kleeff J. How fibrosis influences imaging and surgical decisions in pancreatic cancer. Front Physiol. 2012;3:389. [PMID: 23060813 DOI: 10.3389/fphys.2012.00389] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
207 Arya N, Wyse JM, Jayaraman S, Ball CG, Lam E, Paquin SC, Lightfoot P, Sahai AV. A proposal for the ideal algorithm for the diagnosis, staging, and treatment of pancreas masses suspicious for pancreatic adenocarcinoma: Results of a working group of the Canadian Society for Endoscopic Ultrasound. Endosc Ultrasound 2020;9:154-61. [PMID: 32584310 DOI: 10.4103/eus.eus_28_20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 Serrano PE, Cleary SP, Dhani N, Kim PT, Greig PD, Leung K, Moulton CA, Gallinger S, Wei AC. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods. Ann Surg Oncol 2015;22:1160-7. [PMID: 25348784 DOI: 10.1245/s10434-014-4196-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
209 Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018;268:610-619. [PMID: 30080723 DOI: 10.1097/SLA.0000000000002957] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
210 Guha Majumdar A, Subramanian M. Hydroxychavicol from Piper betle induces apoptosis, cell cycle arrest, and inhibits epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Pharmacol 2019;166:274-91. [PMID: 31154000 DOI: 10.1016/j.bcp.2019.05.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
211 O'mahoney PR, Yeo HL, Sedrakyan A, Trencheva K, Mao J, Isaacs AJ, Lieberman MD, Michelassi F. Centralization of pancreatoduodenectomy a decade later: Impact of the volume–outcome relationship. Surgery 2016;159:1528-38. [DOI: 10.1016/j.surg.2016.01.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
212 Tummers WS, Miller SE, Teraphongphom NT, van den Berg NS, Hasan A, Longacre TA, Fisher GA, Bonsing BA, Vahrmeijer AL, Gambhir SS, Swijnenburg R, Rosenthal EL, Poultsides GA. Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer. HPB 2019;21:883-90. [DOI: 10.1016/j.hpb.2018.11.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
213 Kamarajah SK, Burns WR, Frankel TL, Cho CS, Nathan H. Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. Ann Surg Oncol. 2017;24:2023-2030. [PMID: 28213792 DOI: 10.1245/s10434-017-5810-x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 113] [Article Influence: 31.5] [Reference Citation Analysis]
214 Ielpo B, Caruso R, Duran H, Diaz E, Fabra I, Malavé L, Ferri V, Alvarez R, Cubillo A, Plaza C, Lazzaro S, Kalivaci D, Quijano Y, Vicente E. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Surg Oncol 2017;26:402-10. [PMID: 29113659 DOI: 10.1016/j.suronc.2017.08.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
215 Hain E, Challine A, Tzedakis S, Mare A, Martinino A, Fuks D, Adham M, Piessen G, Regimbeau JM, Buc E, Barbier L, Vaillant JC, Jeune F, Sulpice L, Muscari F, Schwarz L, Deguelte S, Sa Cunha A, Truant S, Dousset B, Sauvanet A, Gaujoux S. Study Protocol of the PreFiPS Study: Prevention of Postoperative Pancreatic Fistula by Somatostatin Compared With Octreotide, a Prospective Randomized Controlled Trial. Front Med (Lausanne) 2020;7:488. [PMID: 33521003 DOI: 10.3389/fmed.2020.00488] [Reference Citation Analysis]
216 Eyff TF, Bosi HR, Toni MS, Zilio MB, Corso CO, Bersch VP, Osvaldt AB. THE ROLE OF IMMUNOINFLAMMATORY MARKERS IN THE PROGNOSIS AND RESECTABILITY OF PANCREATIC ADENOCARCINOMA. Arq Bras Cir Dig 2018;31:e1366. [PMID: 29972394 DOI: 10.1590/0102-672020180001e1366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
217 Hu Y, Qi E, Liu F, Lu Y, Tan S, Sun Y, Han Z, Liang P, Yu X. The application of a three-dimensional visualized seed planning and navigation system in 125I seed implantation for pancreatic cancer. Onco Targets Ther 2018;11:619-27. [PMID: 29440912 DOI: 10.2147/OTT.S141245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]